PT - JOURNAL ARTICLE AU - Towns, Clodagh AU - Fang, Zih-Hua AU - Tan, Manuela M. X. AU - Jasaityte, Simona AU - Schmaderer, Theresa M. AU - Stafford, Eleanor J. AU - Pollard, Miriam AU - Tilney, Russel AU - Hodgson, Megan AU - Wu, Lesley AU - Labrum, Robyn AU - Hehir, Jason AU - Polke, James AU - Lange, Lara M. AU - Schapira, Anthony H. V. AU - Bhatia, Kailash P. AU - Parkinson’s Families Project (PFP) Study Group AU - Global Parkinson’s Genetics Program (GP2) AU - Singleton, Andrew B. AU - Blauwendraat, Cornelis AU - Klein, Christine AU - Houlden, Henry AU - Wood, Nicholas W. AU - Jarman, Paul R. AU - Morris, Huw R. AU - Real, Raquel TI - Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease AID - 10.1101/2023.12.05.23299397 DP - 2024 Jan 01 TA - medRxiv PG - 2023.12.05.23299397 4099 - http://medrxiv.org/content/early/2024/09/10/2023.12.05.23299397.short 4100 - http://medrxiv.org/content/early/2024/09/10/2023.12.05.23299397.full AB - The Parkinson’s Families Project is a UK-wide study aimed at identifying genetic variation associated with familial and early-onset Parkinson’s disease (PD). We recruited individuals with a clinical diagnosis of PD and age at motor symptom onset ≤ 45 years and/or a family history of PD in up to third-degree relatives. Where possible, we also recruited affected and unaffected relatives. We analysed DNA samples with a combination of single nucleotide polymorphism (SNP) array genotyping, multiplex ligation-dependent probe amplification (MLPA), and whole-genome sequencing (WGS). We investigated the association between identified pathogenic mutations and demographic and clinical factors such as age at motor symptom onset, family history, motor symptoms (MDS-UPDRS) and cognitive performance (MoCA). We performed baseline genetic analysis in 718 families, of which 205 had sporadic early-onset PD (sEOPD), 113 had familial early-onset PD (fEOPD), and 400 had late-onset familial PD (fLOPD). 69 (9.6%) of these families carried pathogenic variants in known monogenic PD-related genes. The rate of a molecular diagnosis increased to 28.1% in PD with motor onset ≤ 35 years. We identified pathogenic variants in LRRK2 in 4.2% of families, and biallelic pathogenic variants in PRKN in 3.6% of families. We also identified two families with SNCA duplications and three families with a pathogenic repeat expansion in ATXN2, as well as single families with pathogenic variants in VCP, PINK1, PNPLA6, PLA2G6, SPG7, GCH1, and RAB32. An additional 73 (10.2%) families were carriers of at least one pathogenic or risk GBA1 variant. Most early-onset and familial PD cases do not have a known genetic cause, indicating that there are likely to be further monogenic causes for PD.Competing Interest StatementH.R.M. reports paid consultancy from Biogen, Biohaven, Lundbeck and lecture fees/honoraria from the Wellcome Trust and Movement Disorders Society; H.R.M. is also a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). A.B.S. has received royalty payments related to a diagnostic for stroke. C.K. serves as a medical advisor to Centogene, Retromer Therapeutics, and Takeda, and she received Speakers honoraria from Desitin and Bial. All other authors declare no financial or non-financial competing interests.Funding StatementPFP has received support from the Janet Owen bequest fund, the Walker-Peltz charitable fund, the Medical Research Council (MRC-G1100643), Cure Parkinsons Trust, Parkinsons UK (K-1501), and the National Institute for Health Research (NIHR) Clinical Research Network (CRN) North Thames. This research was funded in part by Aligning Science Across Parkinsons [Grant number: ASAP-000478] through the Michael J. Fox Foundation for Parkinsons Research (MJFF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The London Camden and Kings Cross Research Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data, code, protocols, and key lab materials used and generated in this study are listed in a Key Resource Table alongside their persistent identifiers at 10.5281/zenodo.12549398.